Asah1 — N Acylsphingosine Amidohydrolase 1 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Asah1 — N Acylsphingosine Amidohydrolase 1 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
<div class="infobox infobox-gene"> [@decreased1918]
<table> [@ceramide2019]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ASAH1 — N-Acylsphingosine Amidohydrolase 1</th></tr> [@acid2020]
<tr><td><strong>Gene Symbol</strong></td><td>ASAH1</td></tr> [@targeting]
<tr><td><strong>Full Name</strong></td><td>N-Acylsphingosine Amidohydrolase 1 (Acid Ceramidase)</td></tr>
<tr><td><strong>Chromosome</strong></td><td>8p22</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[4153](https://www.ncbi.nlm.nih.gov/gene/4153)</td></tr>
<tr><td><strong>OMIM</strong></td><td>613468</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000104522</td></tr>
<tr><td><strong>UniProt</strong></td><td>[Q13510](https://www.uniprot.org/uniprot/Q13510)</td></tr>
<tr><td><strong>Protein Name</strong></td><td>Acid Ceramidase</td></tr>
<tr><td><strong>Protein Length</strong></td><td>395 amino acids</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~44 kDa (precursor), ~13+20 kDa (processed)</td></tr>
<tr><td><strong>Brain Expression</strong></td><td>Ubiquitous, high in brain, liver, kidney</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Farber Disease](/diseases/farber-disease)</td></tr>
</table>
</div>
ASAH1 (N-Acylsphingosine Amidohydrolase 1), also known as acid ceramidase (ACDase), is a lysosomal enzyme that catalyzes the hydrolysis of ceramides into sphingosine and free fatty acids. This reaction is a critical step in sphingolipid metabolism and the ceramide signaling pathway. ASAH1 is essential for maintaining lipid homeostasis, and mutations in ASAH1 cause the lysosomal storage disorder Farber disease. Recent research has implicated ASAH1 deficiency in the pathogenesis of neurodegenerative diseases including [Parkinson's disease](/diseases/parkinsons-disease-disease) (PD), [Alzheimer's disease](/diseases/alzheimers-disease) (AD), and amyotrophic lateral sclerosis (ALS), highlighting the importance of ceramide metabolism in neuronal survival.
The ASAH1 gene is located on chromosome 8p22 and consists of approximately 16 exons spanning about 28 kb of genomic DNA. The gene encodes a protein of 395 amino acids that is synthesized as a precursor and processed into a heterodimer.
ASAH1 is ubiquitously expressed throughout the body, with high expression in the brain, liver, and kidney. In the central nervous system, ASAH1 is expressed in:
ASAH1 belongs to the family of ceramidases, which hydrolyze the N-acyl linkage of ceramides. It is an acid-active enzyme (optimal pH ~4.5-5.0) localized primarily in lysosomes.
The ASAH1 protein has several important features:
ASAH1 catalyzes the hydrolytic cleavage of ceramides:
Ceramide + H₂O → Sphingosine + Fatty Acid
This reaction is part of the sphingolipid catabolic pathway and produces:
ASAH1 plays a central role in sphingolipid metabolism:
ASAH1-derived sphingosine and sphingosine-1-phosphate (S1P) serve as important signaling molecules:
ASAH1 has emerged as an important gene in PD pathogenesis. Multiple studies have identified:
| Study | Year | Key Finding |
|-------|------|-------------|
| Bandopadhyay et al. | 2018 | Decreased ASAH1 in PD substantia nigra |
| Yang et al. | 2020 | ASAH1 variants increase PD risk |
| Liu et al. | 2022 | ASAH1 deficiency promotes α-synuclein aggregation |
ASAH1 is implicated in ALS through:
In AD brain:
Biallelic loss-of-function mutations in ASAH1 cause Farber disease:
ASAH1 deficiency leads to ceramide accumulation, which:
Ceramides impair mitochondrial function through:
ASAH1 deficiency contributes to neuroinflammation:
Recombinant human acid ceramidase (rAC) is being developed for therapy:
AAV-delivered- [Parkinson's disease](/diseases/parkinsons-disease)d for:
Asah1 — N Acylsphingosine Amidohydrolase 1 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Asah1 — N Acylsphingosine Amidohydrolase 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following diagram shows the key molecular relationships involving ASAH1 — N-Acylsphingosine Amidohydrolase 1 discovered through SciDEX knowledge graph analysis: